Trial site
Azienda Unita Sanitaria Locale Della Romagna
Lugo, 48022, ItalyNot linked to an institution yet
- 6running trials
- 6closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 24 trials
- Status
- Completed6 trials
- Active, not recruiting4 trials
- Recruiting2 trials
- Lead sponsor
- F. Hoffmann-La Roche AG2 trials
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS2 trials
- Hoffmann-La Roche2 trials
- ARCAGY/ GINECO GROUP1 trial
- Incyte Corp.1 trial
- and 4 more
Running trials
Active, not recruiting
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer
NCT05233982· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· Phase 3· ARCAGY/ GINECO GROUP· Source
Recruiting
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255471· Phase 3· National Cancer Institute, Naples· Source
Active, not recruiting
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination.
2024-516632-99-00· Phase 2· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Active, not recruiting
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578· Phase 2· Mirati Therapeutics Inc.· Source
Active, not recruiting
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567· Phase 3· Hoffmann-La Roche· Source
Completed
Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary peritoneal cancer patients
2024-516629-30-00· Phase 2· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Completed
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)
2023-505035-12-00· Phase 3· F. Hoffmann-La Roche AG· Source
Completed
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
NCT03656536· Phase 3· Incyte Corp.· Source
Report an error